GSK (FKA GLAXOSMITHKLINE INC.) for GSK (FKA GLAXOSMITHKLINE INC.)
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
H.R. 880 - American Research and Competitiveness Act of 2015, provisions related making permanent the research and development (R&D) tax credit No bill # assigned - Tax reform policy issues, issues related to corporate tax reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| JOSEPH MCGOWAN | — |
| STEPHEN SCANGO | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| SARAH J WALSH | — |
| KIMBERLY A WILLIAMS | — |
Trade (domestic/foreign) TRD
No bill # assigned - Trans-Pacific Strategic Economic Partnership Agreement (TPP), provisions related to intellectual property, market access and public health issues No bill # assigned - Transatlantic Trade and Investment Partnership (TTIP), provisions related to market access intellectual property, regulatory harmonization and other issues No bill # assigned - International market access and intellectual property issues No bill # assigned - Canada IP and market access issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| SHIRA KILCOYNE | — |
| JOSEPH MCGOWAN | — |
| STEPHEN SCANGO | — |
| WILLIAM J SCHUYLER | — |
| SARAH J WALSH | — |
| KIMBERLY A WILLIAMS | — |
Copyright/Patent/Trademark CPT
H.R. 9 - Innovation Act, provisions related to patent litigation reform S. 131 - Fair and Immediate Release of Generic Drugs Act, provisions related to patent settlements S. 632 - STRONG Patents Act of 2015, provisions relating to post grant proceedings, bad faith demand letters, and PTO diversion No bill # assigned - Biopharmaceutical innovation policy issues No bill # assigned - Biologics data protection issues No bill # assigned - Intellectual property issues, additional data exclusivity request that was part of 21st Century Cures submission
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| JOSEPH MCGOWAN | — |
| STEPHEN SCANGO | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| SARAH J WALSH | — |
| KIMBERLY A WILLIAMS | — |
Health Issues HCR
H.R. 1547 - Family Health Care Flexibility Act, provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts S. 836 - Family Health Care Flexibility Act, provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts S. 122 - Safe and Affordable Drugs from Canada Act, provisions related to drug importation S. 185 - PATH Act, provisions related to antibiotics and drug approval S. 320 - Medical Innovation Act of 2015, provisions related to NIH funding and covered manufacturer supplemental fees No bill # assigned - Implementation issues relating to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation rulemaking No bill # assigned - 21st Century Cures Initiative and related policy issues No bill # assigned - FDA special medical use, issues related to limited population antibacterial drug approval pathway No bill # assigned - FDA accelerated approval policy issues No bill # assigned - Comparative effectiveness policy issues No bill # assigned - Biopharmaceutical innovation policy issues No bill # assigned - Pharmaceutical supply chain security issues No bill # assigned - 340B policy issues No bill # assigned - Support for COPD national action plan No bill # assigned - FDA proposed rule regarding generic drug labeling under the 1984 Hatch-Waxman amendments to the FDCA No bill # assigned - FDA proposed rule regarding electronic distribution of cContent of Labeling for Human Prescription Drug and Biological products No bill # assigned - Antibiotic Development to Advance Patient Treatment Actprovisions related to antibiotics and drug approval
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| JOSEPH MCGOWAN | — |
| STEPHEN SCANGO | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| SARAH J WALSH | — |
| KIMBERLY A WILLIAMS | — |
Medicare/Medicaid MMM
H.R. 1190 - Protecting Seniors' Access to Medicare Act of 2015, provisions related to the Independent Payment Advisory Board H.R. 1470 - SGR Repeal and Medicare Provider Payment Modernization Act of 2015, provisions related to SGR reform H.R. 4187 - Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act S. 31 - Medicare Prescription Drug Price Negotiation Act of 2015, provisions related to Part D issues S. 141 - Protecting Seniors' Access to Medicare Act of 2015, provisions related to the Independent Payment Advisory Board S. 648 - Medicare Formulary Improvement Act, provisions related to Medicare Part D No bill # assigned - proposals to increase co-payments for Part D beneficiaries receiving the low-income subsidy No bill # assigned - issues related to better use of medicines and comprehensive medication management No bill # assigned - vaccine access and coverage issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| JOSEPH MCGOWAN | — |
| STEPHEN SCANGO | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| SARAH J WALSH | — |
| KIMBERLY A WILLIAMS | — |
Budget/Appropriations BUD
Sen. Con. Res 11 - amendments relevant to the biopharmaceutical industry including Medicare Part D H. Con. Res. 27 - amendments relevant to the biopharmaceutical industry including Medicare Part D
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| JOSEPH MCGOWAN | — |
| STEPHEN SCANGO | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| SARAH J WALSH | — |
| KIMBERLY A WILLIAMS | — |
Tariff (miscellaneous tariff bills) TAR
No bill # assigned - issues related to the temporary duty suspension for preparations, such as tablets or chewing gum, intended to assist smokers to stop smoking (provided for in subheading 2106.90.99)
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| STEPHEN SCANGO | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.